TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression

Abstract

Objective: This study was intended to determine whether antidepressant outcome to SSRIs was associated with catecholamine gene polymorphisms and neuroendocrine factors in patients of Chinese Han ethnicity with MDD.

Method: A total of 290 MDD patients were recruited and received a 6-week randomized double-blinded treatment. Cortisol, adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), 3′-triiodothyronine (T3), thyroxine (T4), free triiodothyronine (fT3), and free thyroxine (fT4) levels were measured at the baseline. Allele, genotype, and haplotype frequencies of catecholamine genes were compared between responders and non-responders, remission and non-remission groups respectively.

Results: We found that genotype frequency of the rs1800544 polymorphism in the DRD4 gene was significantly different between responders and non-responders (P<0.05). Also the frequency of the rs1800544 CG genotype was significantly higher (P<0.05) in responders (51.4%) than that in non-responders (35.8%). No significant difference was found between responders and non-responders, remission and non-remission groups in the SNPs polymorphisms in the TPH, SLC6A2, SLC6A3, or DRD2 genes. The combination of all neuroendocrine factors, clinical characteristics and gene polymorphisms predicted 74.8% of the variation in SSRI response and 65.5% in SSRI remission.

Conclusion: Polymorphisms of the DRD4 gene were associated with SSRI response in Chinese Han MDD patients. A combination of clinical characteristics, neuroendocrine factors, and gene polymorphisms might be able to predict the outcome to SSRIs.

Key words

depression - neuroendocrine factors - genes - DRD4 - pharmacogenetics

• References

• 1 Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extendedrelease formulation. Int J Clin Pract 2007; 61: 702-710
• 2 Machado M, Iskedjian M, Ruiz I et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006; 22: 1825-1837
• 3 Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care inSTAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
• 4 Serretti A, Chiesa A, Calati R et al. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol 2009; 24: 1-18
• 5 Lerer B, Macciardi F. Pharmacogenetics of antidepressant and moodstabilizing drugs: a review of candidategene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255-275
• 6 Jia P, Wang L, Meltzer HY et al. Pathway-based analysis of GWAS datasets: Effective but caution required. Int J Neuropsychopharmacol 2011; 14: 567-572
• 7 López-León S, Janssens AC, González-Zuloeta Ladd AM et al. Meta-analysis of genetic studies on major depressive disorder. Mol Psychiatry 2008; 13: 772-785
• 8 Kim H, Lim SW, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296: 1609-1618
• 9 Yoshida K, Takahashi H, Higuchi H et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161: 1575-1580
• 10 Bosch OG, Seifritz E, Wetter TC. Stress-related depression: neuroendocrine, genetic, and therapeutical aspects. World J Biol Psychiatry 2012; 13: 556-568
• 11 aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 2009; 180: 305-313
• 12 Min W, Liu C, Yang Y et al. Alterations in hypothalamic-pituitary-adrenal/thyroid (HPA/HPT) axes correlated with the clinical manifestations of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 206-211
• 13 Heuser IJ, Schweiger U, Gotthardt U et al. Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 1996; 15: 93-99
• 14 Fraser SA, Kroenke K, Callahan CM et al. Low yield of thyroid-stimulating hormone testing in elderly patients with depression. Gen Hosp Psychiatry 2004; 26: 302-309
• 15 Brouwer JP, Appelhof BC, Peeters RP et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur J Endocrinol 2006; 154: 819-825
• 16 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
• 17 Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98
• 18 Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
• 19 Li Z, Zhang Z, Tang W et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analyisis.bio.x.cn). Cell Res 2009; 19: 519-523
• 20 Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatment. Brain Res 1983; 287: 237-246
• 21 D’Aquila PS, Collu M, Gessa GL et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-373
• 22 Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86: 37-45
• 23 Garriock HA, Delgado P, Kling MA et al. Number of risk genotypes is a risk factor for major depressive disorder: a case control study. Behav Brain Funct 2006; 2: 24
• 24 Serretti A, Zanardi R, Cusin C et al. No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res 2001; 104: 195-203
• 25 Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTR K2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105-1118
• 26 Min WJ, Ma XH, Li T et al. Association of serotonin and norepinephrine transporter gene polymorphisms with the susceptibility to depression. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2009; 26: 388-392 [in Chinese]
• 27 Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9: 225-233
• 28 Baffa A, Hohoff C, Baune BT et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010; 62: 121-131
• 29 Xu Z, Zhang Z, Shi Y et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord 2011; 133: 165-173
• 30 Fuke S, Suo S, Takahashi N et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001; 1: 152-156
• 31 Kirchheiner J, Gründemann D, Schömig E. Contribution of allelic variations in transporters to the phenotype of drug response. J Psychopharmacol 2006; 20: 27-32
• 32 Lavretsky H, Siddarth P, Kumar A et al. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. Int J Geriatr Psychiatry 2008; 23: 55-59
• 33 Serretti A, Zanardi R, Cusin C et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375-380
• 34 Serretti A, Zanardi R, Rossini D et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592
• 35 Arias B, Fabbri C, Gressier F et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013; 67: 41-47
• 36 Yoshida K, Naito S, Takahashi H et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1279-1283
• 37 Peters EJ, Slager SL, McGrath PJ et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889
• 38 Ham BJ, Lee MS, Lee HJ et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005; 15: 229-301
• 39 Hong CJ, Chen TJ, Yu YW et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6: 27-33
• 40 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
• 41 Wang HC, Yeh TL, Chang HH et al. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl) 2011; 213: 773-779
• 42 Illi A, Setälä-Soikkeli E, Viikki M et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009; 20: 1125-1128
• 43 Wang Y, Liu X, Yu Y et al. The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment. Psychiatry Res 2012; 200: 1047-1050
• 44 Brouwer JP, Appelhof BC, Peeters RP et al. Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. Eur J Endocrinol 2006; 154: 819-825
• 45 Joel I, Begley AE, Mulsant BH et al. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry 2014; 22: 167-176
• 46 Fournier JC, DeRubeis RJ, Shelton RC et al. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009; 77: 775-787
• 47 Porcelli S, Drago A, Fabbri C et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36: 87-113